{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:02:32Z","timestamp":1792015352272,"version":"4.4.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.arbres.2024.05.026","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T15:58:27Z","timestamp":1717171107000},"page":"565-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["New Vaccines for Chronic Respiratory Patients"],"prefix":"10.1016","volume":"60","author":[{"given":"Narmeen","family":"Mallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Dacosta","family":"Urbieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Rivero-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco-Javier","family":"Gonzalez-Barcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2024.05.026_bib0755","unstructured":"World Health Organization. Chronic respiratory diseases. Available at: https:\/\/www.who.int\/health-topics\/chronic-respiratory-diseases#tab=tab_1; 2023 [accessed 25 May 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib0760","doi-asserted-by":"crossref","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","article-title":"Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019","volume":"59","year":"2023","journal-title":"EClinicalMedicine."},{"key":"10.1016\/j.arbres.2024.05.026_bib1400","unstructured":"World Health Organization. Asthma. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/asthma; 2023 [accessed 25 May 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1405","doi-asserted-by":"crossref","first-page":"823399","DOI":"10.3389\/fped.2022.823399","article-title":"The Burden of Childhood Asthma by Age Group, 1990-2019: A Systematic Analysis of Global Burden of Disease 2019 Data","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Pediatr."},{"key":"10.1016\/j.arbres.2024.05.026_bib1410","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.suc.2021.12.001","article-title":"Lung Cancer: Epidemiology and Screening","volume":"102","author":"Oliver","year":"2022","journal-title":"Surg Clin North Am."},{"key":"10.1016\/j.arbres.2024.05.026_bib1415","first-page":"1583","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin Med J (Engl)."},{"key":"10.1016\/j.arbres.2024.05.026_bib1420","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1164\/rccm.202302-0289OC","article-title":"Unmet Diagnostic and Therapeutic Opportunities for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Countries","volume":"208","author":"Florman","year":"2023","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1425","unstructured":"World Health Organization. WHO package of essential noncommunicable (?PEN)? disease interventions for primary health care. Available at: https:\/\/apps.who.int\/iris\/handle\/10665\/334186; 2020 [accessed 14 June 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1430","doi-asserted-by":"crossref","first-page":"170103","DOI":"10.1183\/16000617.0103-2017","article-title":"Exacerbations of COPD","volume":"27","author":"Viniol","year":"2018","journal-title":"Eur Respir Rev."},{"key":"10.1016\/j.arbres.2024.05.026_bib1435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/JAA.S121276","article-title":"Environmental triggers and avoidance in the management of asthma","volume":"10","author":"Gautier","year":"2017","journal-title":"J Asthma Allergy."},{"key":"10.1016\/j.arbres.2024.05.026_bib0810","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753465815618113","article-title":"The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma","volume":"10","author":"Hewitt","year":"2016","journal-title":"Ther Adv Respir Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib0815","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fcell.2020.00099","article-title":"Respiratory Viral Infections in Exacerbation of Chronic Airway Inflammatory Diseases: Novel Mechanisms and Insights From the Upper Airway Epithelium","volume":"8","author":"Tan","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.arbres.2024.05.026_bib0820","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1378\/chest.14-1961","article-title":"The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study","volume":"147","author":"Gao","year":"2015","journal-title":"Chest."},{"key":"10.1016\/j.arbres.2024.05.026_bib0825","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.coviro.2018.01.001","article-title":"Transmission routes of respiratory viruses among humans","volume":"28","author":"Kutter","year":"2018","journal-title":"Curr Opin Virol."},{"key":"10.1016\/j.arbres.2024.05.026_bib0830","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaci.2017.08.003","article-title":"Role of viral infections in the development and exacerbation of asthma in children","volume":"140","author":"Jartti","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.arbres.2024.05.026_bib0835","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/rccm.202110-2389CI","article-title":"A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable","volume":"205","author":"Cookson","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib0840","unstructured":"American Lung Association. Controlling Chronic Lung Diseases Amid COVID-19. Available at: https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/covid-19\/chronic-lung-diseases-and-covid; 2023 [accessed August 24 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib0845","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/vaccines11061076","article-title":"Review of Vaccination Recommendations in Guidelines for Non-Communicable Diseases with Highest Global Disease Burden among Adults 75 Years Old and Above","volume":"11","author":"Ishak","year":"2023","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.arbres.2024.05.026_bib1440","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/antibiotics12010138","article-title":"Vaccination against Community-Acquired Pneumonia in Spanish Adults: Practical Recommendations by the NeumoExperts Prevention Group","volume":"12","author":"Redondo","year":"2023","journal-title":"Antibiotics (Basel)."},{"key":"10.1016\/j.arbres.2024.05.026_bib0855","unstructured":"Global Initiative for Asthma. 2023 GINA main report. Available at: https:\/\/ginasthma.org\/2023-gina-main-report\/; 2023 [accessed 17 December 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib0860","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nyas.14958","article-title":"Respiratory viruses: New frontiers-a Keystone Symposia report","volume":"1522","author":"Cable","year":"2023","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.arbres.2024.05.026_bib0865","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/jcm12010111","article-title":"COPD Exacerbation-Related Pathogens and Previous COPD Treatment","volume":"12","author":"Sim","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib0870","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2147\/COPD.S378034","article-title":"The Influence of Influenza Virus Infections in Patients with Chronic Obstructive Pulmonary Disease","volume":"17","author":"Liao","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib0875","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1080\/13696998.2022.2098630","article-title":"Impact of influenza infection on the short- and long-term health of patients with chronic obstructive pulmonary disease","volume":"25","author":"Wallick","year":"2022","journal-title":"J Med Econ."},{"key":"10.1016\/j.arbres.2024.05.026_bib0880","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.rmed.2012.04.008","article-title":"The natural history of community-acquired pneumonia in COPD patients: a population database analysis","volume":"106","author":"Mullerova","year":"2012","journal-title":"Respir Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib0885","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/15412555.2021.1920904","article-title":"Seroprevalence of Bordetella pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort","volume":"18","author":"Wilkinson","year":"2021","journal-title":"COPD."},{"key":"10.1016\/j.arbres.2024.05.026_bib0890","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/jpc.16197","article-title":"Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions","volume":"58","author":"Binns","year":"2022","journal-title":"J Paediatr Child Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib0895","doi-asserted-by":"crossref","first-page":"14680","DOI":"10.3390\/ijerph192214680","article-title":"Impact of Respiratory Syncytial Virus and Influenza Virus Infection in the Adult Population in Spain between 2012 and 2020","volume":"19","author":"Heppe-Montero","year":"2022","journal-title":"Int J Environ Res Public Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib1445","doi-asserted-by":"crossref","first-page":"e220527","DOI":"10.1001\/jamanetworkopen.2022.0527","article-title":"Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018","volume":"5","author":"Hansen","year":"2022","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.arbres.2024.05.026_bib1450","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/EDE.0000000000001092","article-title":"Hospitalizations Associated with Respiratory Syncytial Virus and Influenza in Children Including Children Diagnosed with Asthma","volume":"30","author":"Goldstein","year":"2019","journal-title":"Epidemiology."},{"key":"10.1016\/j.arbres.2024.05.026_bib1455","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1186\/s12879-017-2897-4","article-title":"Risk of mortality associated with respiratory syncytial virus and influenza infection in adults","volume":"17","author":"Kwon","year":"2017","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1460","first-page":"477","article-title":"Pathophysiology of viral-induced exacerbations of COPD","volume":"2","author":"Potena","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1465","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1016\/j.vaccine.2017.09.092","article-title":"Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics","volume":"37","author":"Vekemans","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.arbres.2024.05.026_bib1470","unstructured":"PATH. RSV Vaccine and mAb Snapshot. Available at: https:\/\/media.path.org\/documents\/RSV-snapshot_02JUN2023_clinical-stage_dBtD8W3.pdf?_gl=1*spjd9a*_gcl_au*MTgyNjc3NjgyNi4xNjg1MDEwNjk0*_ga*MjA5MjY2NDc5NC4xNjg1MDEwNjk0*_ga_YBSE7ZKDQM*MTY4NzI1OTcyOC4yLjAuMTY4NzI1OTcyOC42MC4wLjA; 2023 [accessed 20 June 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1475","unstructured":"US Food and Drug Administration. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants; 2023 [accessed August 27 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1480","unstructured":"US Food & Drug Administration. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine; 2023 [accessed 20 June 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1485","unstructured":"Centers for Disease Control and Prevention. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2023. Available at: https:\/\/www.cdc.gov\/mmwr\/volumes\/72\/wr\/mm7229a4.htm#:\u223c:text=In%20May%202023%2C%20the%20Food%20and%20Drug%20Administration%20(FDA),preF)%20vaccine%20(18); 2023 [accessed August 27 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1490","unstructured":"European Medicines Agency. Arexvy. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/arexvy#authorisation-details-section; 2023 [accessed 27 August 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1495","unstructured":"European Medicines Agency. First RSV vaccine to protect infants up to 6 months of age and older adults. Available at: https:\/\/www.ema.europa.eu\/en\/news\/first-rsv-vaccine-protect-infants-6-months-age-older-adults; 2023 [accessed 27 August 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1500","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.arbres.2024.05.026_bib1505","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1510","unstructured":"Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: June 21-23, 2023 Meeting. RSVpreF Older Adults Clinical Development Program Updates. 2023. Available at: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2023-06-21-23.html. [accessed August 27 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1515","unstructured":"Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: June 21-23, 2023 Meeting. GSK's RSVPreF3 OA Vaccine (AREXVY). 2023. Available at: https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/slides-2023-06-21-23.html. [accessed August 27 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1520","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2024 Gold Report. Available at: https:\/\/goldcopd.org\/2024-gold-report\/; 2024 [accessed 17 December 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1525","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/cid\/ciad471","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions","volume":"78","author":"Feldman","year":"2024","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1530","unstructured":"PATH. RSV Clinical Trial Tracker. Available at: https:\/\/www.path.org\/resources\/rsv-and-mab-trial-tracker\/; [accessed 28 June 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1535","unstructured":"Johnson & Johnson. Janssen Provides Portfolio Update. Available at: https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-provides-portfolio-update; 2023. [accessed 01 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1540","unstructured":"Bavarian Nordic. Bavarian Nordic provides update on RSV vaccine program. Available at: https:\/\/www.bavarian-nordic.com\/investor\/news\/news.aspx?news=6808#:\u223c:text=COPENHAGEN%2C%20Denmark%2C%20July%2022%2C,disease%20(LRTD)%20from%20RSV; 2023. [accessed 13 March 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1545","doi-asserted-by":"crossref","first-page":"eaba6466","DOI":"10.1126\/sciimmunol.aba6466","article-title":"A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain","volume":"5","author":"Swanson","year":"2020","journal-title":"Sci Immunol."},{"key":"10.1016\/j.arbres.2024.05.026_bib1550","unstructured":"Icosavax. IVX-A12 RSV\/hMPV BIVALENT PROGRAM. Available at: https:\/\/icosavax.com\/pipeline\/. [accessed 07 June 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1555","unstructured":"NCT04295070. A Phase 1, First in Human, Randomized, Double-blind, Placebo Controlled Study of the Safety, Tolerability, and Immunogenicity of the CodaVax-RSV Vaccine in Healthy Adult Volunteers. Full Text View - ClinicalTrials.gov. Bethesda Natl. Libr. Med. (US). 2020. Jul 9. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04295070; 2020 [accessed November 8 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1560","unstructured":"NCT05281263. A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults. ClinicalTrials.gov. Bethesda Natl. Libr. Med. (US). 2022. Jul 7. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05281263; 2022 [accessed November 7 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1565","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1570","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1575","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1580","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","volume":"7","author":"Simoes","year":"2023","journal-title":"Lancet Child Adolesc Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib1585","unstructured":"Drysdale S. Efficacy of nirsevimab against RSV lower respiratory tract infection hospitalization in infants: preliminary data from the HARMONIE phase 3b trial. Presented at 41st Annual Meeting of the European Society for Paediatric Infectious Diseases in Lisbon, 2023. Available at: https:\/\/2023.espidmeeting.org\/welcome-to-espid\/. [accessed 30 June 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1590","doi-asserted-by":"crossref","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw Open."},{"key":"10.1016\/j.arbres.2024.05.026_bib1595","doi-asserted-by":"crossref","first-page":"2300606","DOI":"10.2807\/1560-7917.ES.2023.28.49.2300606","article-title":"Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain September and October 2023","volume":"28","author":"Martinon-Torres","year":"2023","journal-title":"Euro Surveill."},{"key":"10.1016\/j.arbres.2024.05.026_bib1600","doi-asserted-by":"crossref","unstructured":"Ares-G\u00f3mez S, Mallah N, Santiago-P\u00e9rez MI, Pardo-Seco J, P\u00e9rez-Mart\u00ednez O, Otero-Barr\u00f3s M-T, et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalization for respiratory syncytial virus First results of a population-based longitudinal study in Galicia, Spain. Lancet Infect Dis. 2024; S1473-3099(24):00215-9. https:\/\/doi.org\/10.1016\/S1473-3099(24)00215-9.","DOI":"10.1016\/S1473-3099(24)00215-9"},{"key":"10.1016\/j.arbres.2024.05.026_bib1605","doi-asserted-by":"crossref","first-page":"2400046","DOI":"10.2807\/1560-7917.ES.2024.29.6.2400046","article-title":"Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024","volume":"29","author":"Lopez-Lacort","year":"2024","journal-title":"Euro Surveill."},{"key":"10.1016\/j.arbres.2024.05.026_bib1610","doi-asserted-by":"crossref","first-page":"2400033","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033","article-title":"Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023\/24 season in Luxembourg","volume":"29","author":"Ernst","year":"2024","journal-title":"Euro Surveill."},{"key":"10.1016\/j.arbres.2024.05.026_bib1615","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available at: https:\/\/covid19.who.int\/; 2023 [accessed November 16 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1620","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12879-021-05915-0","article-title":"Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors","volume":"21","author":"Yin","year":"2021","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1625","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaip.2020.11.054","article-title":"Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis","volume":"9","author":"Liu","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.arbres.2024.05.026_bib1630","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S2213-2600(21)00543-9","article-title":"Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1635","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(21)00013-8","article-title":"Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK","volume":"9","author":"Bloom","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1640","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.202009-3533SO","article-title":"Global Initiative for the Diagnosis Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease","volume":"203","author":"Halpin","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1645","unstructured":"Center for Disease Control and Prevention. Respiratory infections and asthma. Available at: https:\/\/www.cdc.gov\/asthma\/respiratory-infections\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/asthma\/respinf.html; 2023 [accessed November 23 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1650","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","article-title":"Spanish COPD Guidelines (GesEPOC) 2021 Updated Pharmacological treatment of stable COPD","volume":"58","author":"Miravitlles","year":"2022","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2024.05.026_bib1655","unstructured":"World Health Organization. COVID-19 vaccine tracker. Available at: https:\/\/covid19.trackvaccines.org\/agency\/who\/; 2023 [accessed July 03 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1660","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/COPD.S394101","article-title":"Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases","volume":"18","author":"Kwok","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1665","doi-asserted-by":"crossref","first-page":"1195908","DOI":"10.3389\/fpubh.2023.1195908","article-title":"Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies","volume":"11","author":"Song","year":"2023","journal-title":"Front Public Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib1670","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","article-title":"Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis","volume":"7","author":"Piechotta","year":"2023","journal-title":"Lancet Child Adolesc Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib1675","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jinf.2023.01.001","article-title":"Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron variant: A systematic review and meta-analysis","volume":"86","author":"Li","year":"2023","journal-title":"J Infect."},{"key":"10.1016\/j.arbres.2024.05.026_bib1680","unstructured":"World Health Organization. Report of the meeting of the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) held on 16-17 March 2023. Available at: https:\/\/www.who.int\/news\/item\/14-04-2023-report-of-the-meeting-of-the-who-technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)-held-on-16-17-march-2023; 2023 [accessed 27 August 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1685","unstructured":"European Centre for Disease Prevention and Control (ECDC). ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants. Available at: https:\/\/www.ecdc.europa.eu\/en\/news-events\/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants; 2023 [accessed 27 August 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1690","unstructured":"World Health Organization. COVID-19 vaccine tracker and landscape. Available at: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines; 2023 [accessed July 03 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1695","unstructured":"World Health Organization. Influenza (seasonal). Available at: https:\/\/www.who.int\/westernpacific\/health-topics\/influenza-seasonal#tab=tab_1; 2023 [accessed June 10 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1700","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/imj.13213","article-title":"Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital","volume":"46","author":"Biancardi","year":"2016","journal-title":"Intern Med J."},{"issue":"10127","key":"10.1016\/j.arbres.2024.05.026_bib1705","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: a modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.arbres.2024.05.026_bib1710","doi-asserted-by":"crossref","first-page":"e1003550","DOI":"10.1371\/journal.pmed.1003550","article-title":"Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis","volume":"18","author":"Lafond","year":"2021","journal-title":"PLoS Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1715","unstructured":"Portal EVI. Influenza. Available at: https:\/\/vaccination-info.eu\/en\/disease-factsheets\/influenza#:\u223c:text=Vaccination%20is%20the%20most%20effective,individuals%20with%20chronic%20medical%20conditions; 2023 [accessed July 10 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1720","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/adc.2003.030999","article-title":"Effectiveness of influenza vaccine for the prevention of asthma exacerbations","volume":"89","author":"Christy","year":"2004","journal-title":"Arch Dis Child."},{"key":"10.1016\/j.arbres.2024.05.026_bib1725","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1081\/JAS-120026084","article-title":"Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations","volume":"41","author":"Abadoglu","year":"2004","journal-title":"J Asthma."},{"key":"10.1016\/j.arbres.2024.05.026_bib1730","doi-asserted-by":"crossref","first-page":"100277","DOI":"10.1016\/j.opresp.2023.100277","article-title":"GEMA 5.3 Spanish Guideline on the Management of Asthma","volume":"5","author":"Plaza Moral","year":"2023","journal-title":"Open Respir Arch."},{"key":"10.1016\/j.arbres.2024.05.026_bib1735","unstructured":"Centers for Disease Control and Prevention. Prevent Seasonal Flu. Available at: https:\/\/www.cdc.gov\/flu\/prevent\/index.html; 2023 [accessed July 10 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1740","unstructured":"Centers for Disease Control and Prevention. Different Types of Flu Vaccines. Available at: https:\/\/www.cdc.gov\/flu\/prevent\/different-flu-vaccines.htm; 2023 [accessed July 10 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1745","article-title":"Recommendations for Prevention and Control of Influenza in Children, 2022-2023","volume":"150","year":"2022","journal-title":"Pediatrics."},{"key":"10.1016\/j.arbres.2024.05.026_bib1750","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/cid\/cix524","article-title":"Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis","volume":"65","author":"Vasileiou","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1755","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/resp.14309","article-title":"Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations","volume":"27","author":"Li","year":"2022","journal-title":"Respirology."},{"key":"10.1016\/j.arbres.2024.05.026_bib1760","doi-asserted-by":"crossref","first-page":"e0262072","DOI":"10.1371\/journal.pone.0262072","article-title":"Influenza vaccine in chronic obstructive pulmonary disease among elderly male veterans","volume":"17","author":"Young-Xu","year":"2022","journal-title":"PLoS One."},{"key":"10.1016\/j.arbres.2024.05.026_bib1765","first-page":"85","article-title":"Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013 February 2019","volume":"8","year":"2019","journal-title":"Wkly Epidemiol Rec."},{"key":"10.1016\/j.arbres.2024.05.026_bib1770","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/01.inf.0000049347.42983.77","article-title":"Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae","volume":"22","author":"O\u2019Brien","year":"2003","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.arbres.2024.05.026_bib1775","unstructured":"World Health Organization. Global Action Plan for Prevention and Control of Pneumonia (?GAPP)?. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-FCH-CAH-NCH-09.04; 2008 [accessed July 19 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1780","unstructured":"World Health Organization. Pneumonia in children. 2022. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/pneumonia. [accessed 19 July 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1785","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/14760584.2023.2256394","article-title":"A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom","volume":"22","author":"Campling","year":"2023","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.arbres.2024.05.026_bib1790","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","article-title":"Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease","volume":"70","author":"Torres","year":"2015","journal-title":"Thorax."},{"key":"10.1016\/j.arbres.2024.05.026_bib1795","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/1469-0691.12182","article-title":"Invasive pneumococcal disease in patients with an underlying pulmonary disorder","volume":"19","author":"Inghammar","year":"2013","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.arbres.2024.05.026_bib1255","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1513\/AnnalsATS.202004-352OC","article-title":"Inhaled Corticosteroids Use and Risk of Invasive Pneumococcal Disease in a Population-based Study","volume":"17","author":"Toren","year":"2020","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.arbres.2024.05.026_bib1260","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults Hospitalized With Pneumonia in the United States: Incidence Epidemiology, and Mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1265","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cmi.2019.06.025","article-title":"Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes","volume":"26","author":"Bordon","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.arbres.2024.05.026_bib1270","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1056\/NEJMoa044113","article-title":"Asthma as a risk factor for invasive pneumococcal disease","volume":"352","author":"Talbot","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1275","first-page":"1102","article-title":"Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23)","volume":"59","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.arbres.2024.05.026_bib1280","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2213-2600(22)00494-5","article-title":"GOLD COPD report: 2023 update","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1285","unstructured":"UK Health Security Agency. Guidance. Pneumococcal: the green book, chapter 25. Available at: https:\/\/www.gov.uk\/government\/publications\/pneumococcal-the-green-book-chapter-25; 2023 [accessed 19 December 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1290","unstructured":"Center for Disease Control and Prevention. Shared Clinical Decision-Making PCV20 Vaccination for Adults 65 Years or Older. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/who-when-to-vaccinate.html; 2023[accessed October 30 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1295","unstructured":"Prevention CDC. Pneumococcal Polysaccharide VIS. Available at: https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/ppv.html; 2019 [accessed 28 July 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1300","doi-asserted-by":"crossref","first-page":"230034","DOI":"10.1183\/16000617.0034-2023","article-title":"The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus","volume":"32","author":"Simon","year":"2023","journal-title":"Eur Respir Rev."},{"key":"10.1016\/j.arbres.2024.05.026_bib1305","doi-asserted-by":"crossref","first-page":"e0169368","DOI":"10.1371\/journal.pone.0169368","article-title":"Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis","volume":"12","author":"Falkenhorst","year":"2017","journal-title":"PLoS One."},{"key":"10.1016\/j.arbres.2024.05.026_bib1310","unstructured":"Musher D.M., Rodriguez-Barradas M.C. Pneumococcal vaccination in adults. Available at: https:\/\/www.uptodate.com\/contents\/pneumococcal-vaccination-in-adults\/print; 2023 [accessed 28 July 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1315","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal Phase 3 Randomized Clinical Trial of the Safety Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged \u2265 18 Years","volume":"75","author":"Essik","year":"2022","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1320","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1016\/j.vaccine.2021.07.004","article-title":"A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age","volume":"39","author":"Klein","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.arbres.2024.05.026_bib1325","doi-asserted-by":"crossref","first-page":"7494","DOI":"10.1016\/j.vaccine.2021.10.032","article-title":"A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u2265 65 years of age with different prior pneumococcal vaccination","volume":"39","author":"Cannon","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.arbres.2024.05.026_bib1330","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1080\/13696998.2022.2152235","article-title":"Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23","volume":"25","author":"Olsen","year":"2022","journal-title":"J Med Econ."},{"key":"10.1016\/j.arbres.2024.05.026_bib1335","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","article-title":"Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease","volume":"22","author":"Mendes","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"10.1016\/j.arbres.2024.05.026_bib1340","unstructured":"Center for Disease Control and Prevention. Pneumococcal Conjugate VIS (Interim). Available at: https:\/\/www.cdc.gov\/vaccines\/hcp\/vis\/vis-statements\/pcv.html#:\u223c:text=Pneumococcal%20conjugate%20vaccine%20helps%20protect,on%20age%20and%20medical%20status; 2023 [accessed 28 July 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1345","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.arbres.2024.05.026_bib1800","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1355","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/ofid\/ofab466.1241","article-title":"Development of a Next Generation 30+Valent Pneumococcal Conjugate Vaccine (VAX-XP) Using Site-Specific Carrier Protein Conjugation","volume":"8","author":"Behrens","year":"2021","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.arbres.2024.05.026_bib1360","unstructured":"World Health Organization. Pertussis. Available at: https:\/\/www.who.int\/teams\/health-product-policy-and-standards\/standards-and-specifications\/vaccine-standardization\/pertussis; 2023 [accessed 28 July 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1365","unstructured":"Centers for Disease Control and Prevention. Whooping Cough (Pertussis) Vaccination. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/pertussis\/index.html; 2023 [accessed 28 July 2023]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1370","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12916-020-01699-3","article-title":"The burden of laboratory-confirmed pertussis in low- and middle-income countries since the inception of the Expanded Programme on Immunisation (EPI) in 1974: a systematic review and meta-analysis","volume":"18","author":"Muloiwa","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1805","first-page":"93","article-title":"Pneumococcal conjugate vaccine for childhood immunization--WHO position paper","volume":"82","year":"2007","journal-title":"Wkly Epidemiol Rec."},{"key":"10.1016\/j.arbres.2024.05.026_bib1380","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.arbres.2021.06.021","article-title":"Whooping Cough: The Visible Enemy","volume":"58","author":"Gonzalez-Barcala","year":"2022","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2024.05.026_bib1385","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/21645515.2019.1652517","article-title":"The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context","volume":"16","author":"Blasi","year":"2020","journal-title":"Hum Vaccin Immunother."},{"key":"10.1016\/j.arbres.2024.05.026_bib1390","doi-asserted-by":"crossref","first-page":"100153","DOI":"10.1016\/j.opresp.2021.100153","article-title":"Pertussis Vaccine in COPD and Asthma: An Old Acquaintance Is Back","volume":"4","author":"Villar-Alvarez","year":"2022","journal-title":"Open Respir Arch."},{"key":"10.1016\/j.arbres.2024.05.026_bib1395","article-title":"Using open source data to estimate the global epidemiology of pertussis","volume":"4","author":"Stone","year":"2020","journal-title":"Global Biosecurity."},{"key":"10.1016\/j.arbres.2024.05.026_bib1810","first-page":"433","article-title":"Pertussis vaccines: WHO position paper \u2013 August 2015","volume":"35","year":"2015","journal-title":"Wkly Epidemiol Rec."},{"key":"10.1016\/j.arbres.2024.05.026_bib1815","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/j.jval.2023.03.2513","article-title":"EE535 Economic Evaluation of Decennial Pertussis Vaccination with Tetanus, Diphtheria and Acellular Pertussis (TDAP) Vaccine in Adult Populations with Asthma or Chronic Obstructive Pulmonary Disease (COPD) in Brazil","volume":"26","author":"de Veras","year":"2023","journal-title":"Value Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib1820","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1038\/s41598-023-38355-8","article-title":"Immune response to pertussis vaccine in COPD patients","volume":"13","author":"Feredj","year":"2023","journal-title":"Sci Rep."},{"key":"10.1016\/j.arbres.2024.05.026_bib1825","unstructured":"Jones J. Evidence to recommendations framework: Nirsevimab updates. Center for Disease Control and Prevention, Advisory Committee on Immunization Practices meeting. Atlanta. Available at: https:\/\/stacks.cdc.gov\/view\/cdc\/131586; 2023 [accessed 15 September 2023]"},{"key":"10.1016\/j.arbres.2024.05.026_bib1830","first-page":"100629","article-title":"Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study","volume":"28","author":"Shoukat","year":"2023","journal-title":"Lancet Reg Health Am."},{"key":"10.1016\/j.arbres.2024.05.026_bib1835","first-page":"100657","article-title":"Pricey or priceless: cost-effectiveness of respiratory syncytial virus (RSV) prevention in infants","volume":"29","author":"Li","year":"2024","journal-title":"Lancet Reg Health Am."},{"key":"10.1016\/j.arbres.2024.05.026_bib1840","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.vaccine.2023.01.058","article-title":"Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries","volume":"41","author":"Getaneh","year":"2023","journal-title":"Vaccine."},{"key":"10.1016\/j.arbres.2024.05.026_bib1845","doi-asserted-by":"crossref","first-page":"06001","DOI":"10.7189\/jogh.13.06001","article-title":"Economic evaluation of COVID-19 vaccination: A systematic review","volume":"13","author":"Utami","year":"2023","journal-title":"J Glob Health."},{"key":"10.1016\/j.arbres.2024.05.026_bib1850","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/jebm.12525","article-title":"Cost-effectiveness of COVID-19 vaccination: A systematic review","volume":"16","author":"Fu","year":"2023","journal-title":"J Evid Based Med."},{"key":"10.1016\/j.arbres.2024.05.026_bib1855","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/vaccines10010059","article-title":"A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia","volume":"10","author":"L\u00f3pez","year":"2021","journal-title":"Vaccines (Basel)."},{"key":"10.1016\/j.arbres.2024.05.026_bib1860","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.vaccine.2018.11.056","article-title":"Cost-effectiveness of adult vaccinations: A systematic review","volume":"37","author":"Leidner","year":"2019","journal-title":"Vaccine."},{"key":"10.1016\/j.arbres.2024.05.026_bib1865","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/13696998.2023.2194193","article-title":"Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal","volume":"26","author":"Alvarez","year":"2023","journal-title":"J Med Econ."},{"key":"10.1016\/j.arbres.2024.05.026_bib1870","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1055\/s-0035-1570346","article-title":"Definition of levels of evidence (LoE) and overall strength of evidence (SoE)","volume":"5","year":"2015","journal-title":"Global Spine J."},{"key":"10.1016\/j.arbres.2024.05.026_bib1875","unstructured":"GSK Canada. Product monograph including patient medication information. Arexvy. Available at: https:\/\/ca.gsk.com\/media\/6988\/arexvy.pdf; 2023 [accessed 24 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1880","unstructured":"PFIZER. ABRYSVO- respiratory syncytial virus vaccine. Available at: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19589#section-4; 2024 [accessed 24 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1885","unstructured":"Centers for Disease Control and Prevention. BEYFORTUS. Highlights of prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf; 2023 [accessed 24 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1890","unstructured":"Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States. Available at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html; 2024 [accessed 24 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1895","unstructured":"Prevention CDC. Who should and who should not get a flu vaccine. Available at: https:\/\/www.cdc.gov\/flu\/prevent\/whoshouldvax.htm#anchor_1555704832; 2024 [accessed 26 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1900","unstructured":"Sanofi. Important safety information. Available at: https:\/\/www.sanofiflu.com\/fluzone-high-dose-influenza-vaccine\/; 2024 [accessed 26 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1905","unstructured":"Prevention CDC. Pneumococcal vaccine recommendations, https:\/\/www.cdc.gov\/vaccines\/vpd\/pneumo\/hcp\/recommendations.html; 2024 [accessed 26 April 2024]."},{"key":"10.1016\/j.arbres.2024.05.026_bib1910","unstructured":"Centers for Disease Control and Prevention. Pertussis. Available at: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/pert.html; 2022 [accessed 26 April 2024]."}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028962400190X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030028962400190X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T14:06:26Z","timestamp":1728137186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030028962400190X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":149,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S030028962400190X"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2024.05.026","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Vaccines for Chronic Respiratory Patients","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2024.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEPAR.","name":"copyright","label":"Copyright"}]}}